Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (204)
  • Open Access

    REVIEW

    Spliceosome-mediated RNA trans-splicing: a strategy for Huntington’s disease gene therapy

    QINGYANG ZHANG, SHUXIAN HUANG, DAN WENG*

    BIOCELL, Vol.48, No.10, pp. 1443-1453, 2024, DOI:10.32604/biocell.2024.053794 - 02 October 2024

    Abstract Huntington’s disease (HD) is a debilitating neurodegenerative disorder caused by an abnormal expansion of CAG repeats (Cytosine, Adenine, Guanine) in the huntingtin gene (HTT). This mutation leads to the production of a mutant huntingtin protein, resulting in neuronal dysfunction and cell death. Current treatments primarily focus on symptomatic relief and do not address the underlying genetic cause. This review explores spliceosome-mediated RNA trans-splicing (SMaRT) therapy as an innovative and potential approach for HD treatment. SMaRT leverages the cell’s natural splicing machinery to correct mutant mRNA, thereby reducing toxic protein levels while restoring functional protein production. We More >

  • Open Access

    REVIEW

    Pioneering a new era in Parkinson’s disease management through adipose-derived mesenchymal stem cell therapy

    MOHAMMAD-SADEGH LOTFI, FATEMEH B. RASSOULI*

    BIOCELL, Vol.48, No.10, pp. 1419-1428, 2024, DOI:10.32604/biocell.2024.053597 - 02 October 2024

    Abstract Parkinson’s disease (PD) is one of the fastest-growing neurodegenerative disorders worldwide. So far, PD treatments only offer little clinical relief and cannot reverse or stop the disease progression. Stem cell (SC) therapy is a rapidly evolving technology that holds significant promise for enhancing current therapeutic approaches. Adipose-derived mesenchymal SCs (AD-MSCs) have many features such as easy harvest with minimal invasive techniques, high plasticity, non-immunogenicity, and no ethical issues, which have made them suitable choices for clinical applications in regenerative research. AD-MSCs are ideal tools to treat PD, as they have the potential to differentiate into… More >

  • Open Access

    REVIEW

    Neural stem cell-derived exosomes: a cell-free transplant for potential cure of neurological diseases

    JIAJUN HUANG1,#, WEI WANG1,#, WENTONG LIN2, HENGSEN CAI3, ZHIHAN ZHU1, WAQAS AHMED4, QIANKUN ZHANG1, JIALE LIU1, YIFAN ZHANG1, RONG LI1, ZHINUO LI1, AHSAN ALI KHAN5, DENG LU3, YONG HU6, LUKUI CHEN1,*

    BIOCELL, Vol.48, No.10, pp. 1405-1418, 2024, DOI:10.32604/biocell.2024.053148 - 02 October 2024

    Abstract Degeneration and death of nerve cells are inevitable with the occurrence and progression of nervous system disorders. Researchers transplanted neural stem cells into relevant areas, trying to solve the difficulty of neural cell loss by differentiating neural stem cells into various nerve cells. In recent years, however, studies have shown that transplanted neural stem cells help neural tissues regenerate and return to normal through paracrine action rather than just replacing cells. Exosomes are essential paracrine mediators, which can participate in cell communication through substance transmission. In this regard, this review mainly discusses the current research More >

  • Open Access

    REVIEW

    Glutamine transporters as effective targets in digestive system malignant tumor treatment

    FEI CHU1, KAI TONG1, XIANG GU1, MEI BAO1, YANFEN CHEN1, BIN WANG2, YANHUA SHAO1, LING WEI1,*

    Oncology Research, Vol.32, No.10, pp. 1661-1671, 2024, DOI:10.32604/or.2024.048287 - 18 September 2024

    Abstract Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively More > Graphic Abstract

    Glutamine transporters as effective targets in digestive system malignant tumor treatment

  • Open Access

    REVIEW

    mRNA vaccines: a new era in vaccine development

    SHUBHRA CHANDRA1,2, JENNIFER C. WILSON1,2, DAVID GOOD3, MING Q. WEI1,2,*

    Oncology Research, Vol.32, No.10, pp. 1543-1564, 2024, DOI:10.32604/or.2024.043987 - 18 September 2024

    Abstract The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body’s innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized… More > Graphic Abstract

    mRNA vaccines: a new era in vaccine development

  • Open Access

    VIEWPOINT

    Non-canonical BRAF variants and rearrangements in hairy cell leukemia

    STEPHEN E. LANGABEER*

    Oncology Research, Vol.32, No.9, pp. 1423-1427, 2024, DOI:10.32604/or.2024.051218 - 23 August 2024

    Abstract Hairy cell leukemia (HCL) is an uncommon mature B-cell malignancy characterized by a typical morphology, immunophenotype, and clinical profile. The vast majority of HCL patients harbor the canonical BRAF V600E mutation which has become a rationalized target of the subsequently deregulated RAS-RAF-MEK-MAPK signaling pathway in HCL patients who have relapsed or who are refractory to front-line therapy. However, several HCL patients with a classical phenotype display non-canonical BRAF mutations or rearrangements. These include sequence variants within alternative exons and an oncogenic fusion with the IGH gene. Care must be taken in the molecular diagnostic work-up of patients More >

  • Open Access

    REVIEW

    Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR–T) cell immunotherapy

    ZHENGYI WANG1,*, LIANG ZHOU1, XIAOYING WU2

    Oncology Research, Vol.32, No.9, pp. 1479-1516, 2024, DOI:10.32604/or.2024.048564 - 23 August 2024

    Abstract Chimeric antigen receptor T-cesll therapy (CAR–T) has achieved groundbreaking advancements in clinical application, ushering in a new era for innovative cancer treatment. However, the challenges associated with implementing this novel targeted cell therapy are increasingly significant. Particularly in the clinical management of solid tumors, obstacles such as the immunosuppressive effects of the tumor microenvironment, limited local tumor infiltration capability of CAR–T cells, heterogeneity of tumor targeting antigens, uncertainties surrounding CAR–T quality, control, and clinical adverse reactions have contributed to increased drug resistance and decreased compliance in tumor therapy. These factors have significantly impeded the widespread More > Graphic Abstract

    Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR–T) cell immunotherapy

  • Open Access

    REVIEW

    The Effectiveness of Psychotherapy on Posttraumatic Stress Disorder in Soldier: A Systematic Review

    Wencen Lan, Bin Wang*, Gai Li, Jianming Liu

    International Journal of Mental Health Promotion, Vol.26, No.7, pp. 499-516, 2024, DOI:10.32604/ijmhp.2024.052309 - 30 July 2024

    Abstract The objective of this systematic review is to examine the effectiveness of psychotherapy in treating Post-Traumatic Stress Disorder (PTSD) in military personnel. PubMed, Web of Science, The Cochrane Library, EBSCO and CNKI databases were searched from 1 January, 2000 to November 2022 for Randomized Controlled Trials (RCTs) on psychotherapeutic interventions for military PTSD. The physical Therapy Evidence Database (PEDro) scale was used to evaluate the quality of the literature. Two researchers conducted literature screening, data extraction, and risk bias assessment in accordance with inclusion and exclusion criteria. Ultimately, 49 RCTs were included, involving a total… More >

  • Open Access

    REVIEW

    Three-dimensional cell-based strategies for liver regeneration

    DAN GUO1, XI XIA2,*, JIAN YANG1,*

    BIOCELL, Vol.48, No.7, pp. 1023-1036, 2024, DOI:10.32604/biocell.2024.051095 - 03 July 2024

    Abstract Liver regeneration and the development of effective therapies for liver failure remain formidable challenges in modern medicine. In recent years, the utilization of 3D cell-based strategies has emerged as a promising approach for addressing these urgent clinical requirements. This review provides a thorough analysis of the application of 3D cell-based approaches to liver regeneration and their potential impact on patients with end-stage liver failure. Here, we discuss various 3D culture models that incorporate hepatocytes and stem cells to restore liver function and ameliorate the consequences of liver failure. Furthermore, we explored the challenges in transitioning More >

  • Open Access

    ARTICLE

    Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma

    LISANNE K.A. NEIJENHUIS1,2,3,#, LEUTA L. NAUMANN4,#, SONIA A.M. FERKEL1, SAMUEL J.S. RUBIN1, STEPHAN ROGALLA1,*

    Oncology Research, Vol.32, No.7, pp. 1163-1172, 2024, DOI:10.32604/or.2024.050907 - 20 June 2024

    Abstract Background: Osteosarcoma is the most common malignant primary bone tumor. The prognosis for patients with disseminated disease remains very poor despite recent advancements in chemotherapy. Moreover, current treatment regimens bear a significant risk of serious side effects. Thus, there is an unmet clinical need for effective therapies with improved safety profiles. Taurolidine is an antibacterial agent that has been shown to induce cell death in different types of cancer cell lines. Methods: In this study, we examined both the antineoplastic and antiangiogenic effects of taurolidine in animal models of osteosarcoma. K7M2 murine osteosarcoma cells were… More >

Displaying 1-10 on page 1 of 204. Per Page